Table 1. Clinical improvements associated with R. mucosa treatment.
Summary of clinical outcomes. SCORAD, EASI, and pruritus values for study participants are shown together with rates of improvement.
| SCORAD measures | Dose escalation n = 15 | 105 CFU/body site dose n = 5 | Total n = 20 |
|---|---|---|---|
|
| |||
| SCORAD50 | 80.0% | 100% | 85% |
|
| |||
| SCORAD75 | 33.3% | 40% | 35% |
|
| |||
| Mean % improvement in SCORAD | 64.3% | 69.4% | 65.6% |
| EASI measures | |||
|
| |||
| Mean baseline EASI score | 7.2 | 9.5 | 7.8 |
|
| |||
| Mean week 16 EASI score | 1.3 | 1.8 | 1.4 |
|
| |||
| Mean % improvement in EASI | 75.6% | 80.5% | 76.8% |
|
| |||
| EASI50 | 86.7% | 100.0% | 90.0% |
|
| |||
| EASI75 | 66.7% | 80.0% | 70.0% |
|
| |||
| EASI90 | 40.0% | 0.0% | 30.0% |
| Pruritus measures | |||
|
| |||
| Mean baseline pruritus score | 6.4 | 7.1 | 6.6 |
|
| |||
| Mean week 16 pruritus score | 2.3 | 3.4 | 2.6 |
|
| |||
| Mean % improvement | 59.7% | 51.0% | 57.6% |